What are treatment options for resistance to or intolerance of first-line TKIs in chronic myelogenous leukemia (CML)?

Updated: Oct 23, 2019
  • Author: Rossa Khalaf, MD; Chief Editor: Emmanuel C Besa, MD  more...
  • Print
Answer

Answer

The risk of progression is high after failure of dasatinib or nilotinib, and no clear evidence suggests that switching to different TKI in such cases will improve long-term outcomes. [19] Options include the following:


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!